News

HDSA 2025: Early planning key for navigating care over time

Taking steps to plan ahead, including having difficult discussions early on, can help people with Huntington’s disease and their families navigate life as the disease progresses and care needs evolve. That’s according to speakers at the Huntington’s Disease Society of America (HDSA) annual convention, held June 26-28 in…

HDSA 2025: Psychedelic compound eases depression in mice

Treatment with a nonhallucinogenic psychedelic compound may help to ease depression in people with Huntington’s disease, according to experiments done in a mouse model. The research was done by Kaleigh Hanley, a scientist at the University of Central Florida’s College of Medicine. Hanley is one of the recipients of…

HDSA 2025: Support can help combat Huntington’s disease stigma

People affected by Huntington’s disease often experience stigma, but — according to two social workers, and patients themselves — this can be combated by building loving communities and being proactive about sharing experiences and asking for support. At the 40th annual convention of the Huntington’s Disease Society of…

HDSA 2025: Community gathers for 40th annual convention

Today kicks off the 40th annual convention of the Huntington’s Disease Society of America (HDSA), an event the association says provides an opportunity for the Huntington’s disease community to come together to “learn, share, and build hope for the future.” This year’s convention is taking place in…

Smartphone-based tests may better detect Huntington’s progression

The Huntington’s Disease Digital Motor Score (HDDMS), a new measure based on four motor tests that are done through a smartphone app, may be able to detect Huntington’s disease progression with greater sensitivity than current standard tools, a study reports. “Our findings suggest that incorporating the HDDMS in clinical trials…

uniQure eyes 2026 for AMT-130 approval application in US

uniQure plans to submit a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) early next year seeking approval of its gene therapy candidate AMT-130 for Huntington’s disease. Top-line, three-year data from the ongoing clinical trials that will support that application are due in the…